相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice
Susanne Schuster et al.
SCIENTIFIC REPORTS (2019)
P5367Indirect comparison of the safety and efficacy of alirocumab and evolocumab: from a comprehensive meta-analysis of 30 randomized controlled trials
P Guedeney et al.
EUROPEAN HEART JOURNAL (2019)
No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data
Philip D. Harvey et al.
EUROPEAN HEART JOURNAL (2018)
Testing cognitive functions in rodent disease models: Present pitfalls and future perspectives
Heikki Tanila
BEHAVIOURAL BRAIN RESEARCH (2018)
PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment Reasons for Geographic and Racial Differences in Stroke Study (REGARDS)
Matthew T. Mefford et al.
CIRCULATION (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cognitive Function in a Randomized Trial of Evolocumab
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia Results Up to 4 Years From the Open-Label OSLER-1 Extension Study
Michael J. Koren et al.
JAMA CARDIOLOGY (2017)
Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date
Terry McCormack et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2016)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE
Brandon Ason et al.
JOURNAL OF LIPID RESEARCH (2014)
Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
Susan Kuhnast et al.
JOURNAL OF LIPID RESEARCH (2014)
The novel object recognition memory: neurobiology, test procedure, and its modifications
M. Antunes et al.
COGNITIVE PROCESSING (2012)
Folate deficiency induces neurodegeneration and brain dysfunction in mice lacking uracil DNA glycosylase
Golo Kronenberg et al.
JOURNAL OF NEUROSCIENCE (2008)
Anxious and hyperactive phenotype following brief ischemic episodes in mice
B Winter et al.
BIOLOGICAL PSYCHIATRY (2005)
Dysexecutive syndrome after mild cerebral ischemia? Mice learn normally but have deficits in strategy switching
B Winter et al.
STROKE (2004)
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):: Liver regeneration and neuronal differentiation
NG Seidah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
分享论文
